Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Darragh O’Brien has secured a prestigious Alzheimer’s Research UK Senior Research Fellowship to uncover how healthy tau turns harmful - targeting the earliest stages of Alzheimer’s disease and opening new possibilities for treatments that could stop neurodegeneration before irreversible damage begins.

With effective treatments for Alzheimer’s disease still urgently needed, understanding the molecular events that set neurodegeneration in motion is a critical challenge. Darragh O’Brien has been awarded a prestigious Senior Research Fellowship from Alzheimer’s Research UK to tackle this challenge by uncovering some of the earliest changes in tau, a protein at the heart of Alzheimer’s disease and other neurodegenerative disorders. His research will investigate how healthy, soluble tau changes shape and begins assembling into harmful structures, potentially revealing new opportunities to target the disease process before large, established protein aggregates have formed.

  Dr Darragh O'Brien Inspect

“Tau is an extraordinarily dynamic protein, and that flexibility is fundamental to its normal function. But it also presents a major challenge: some of the structural changes that may be most important in disease are precisely the ones that are hardest to capture,” said Dr O’Brien. “This fellowship will allow me to investigate that critical transition from normal tau towards the early assemblies that ultimately lead to pathological aggregation. By understanding these changes, I hope to identify molecular features that distinguish healthy from disease-associated tau and reveal new ways of targeting the disease process.”

For Darragh, the fellowship also has a strong personal significance. “Having experienced first-hand the devastating impact of dementia, this research is deeply personal to me and a constant reminder of why our work matters. This fellowship gives me and my team an invaluable opportunity to deepen our understanding of Alzheimer’s and related disorders and, ultimately, help pave the way towards new medicines and better outcomes for people affected by dementia.”